For about 3 to 8 percent of menstruating women in the US, the days before each period bring not just irritability or bloating but disabling depression, anxiety, anger, or panic that lifts within days of bleeding starting. PMDD — premenstrual dysphoric disorder — was added to the DSM-5 in 2013 as a distinct mood disorder, recognizing what many women had described for years: that a small fraction of premenstrual symptom syndromes are far more severe than ordinary PMS and warrant targeted treatment.
What PMDD Is and How Common It Is
PMDD is a cyclic mood disorder in which severe affective and physical symptoms occur during the luteal phase of the menstrual cycle (the week before menstruation), remit within a few days of menses onset, and are absent during the postmenstrual week. The DSM-5 requires symptoms during most cycles in the past year, prospective symptom tracking for at least two cycles to confirm the cyclical pattern, and significant impact on work, school, relationships, or social functioning.
According to the American College of Obstetricians and Gynecologists, PMDD affects approximately 3 to 8 percent of menstruating women, distinct from the much larger group with milder premenstrual syndrome. Onset typically occurs in the late teens or 20s, and symptoms often worsen in perimenopause before resolving with menopause. For broader context on cyclical mood disorders, see our medical conditions resource.
Causes
The exact cause of PMDD is not fully understood. Current evidence points to abnormal sensitivity to normal hormonal fluctuations rather than abnormal hormone levels themselves. Allopregnanolone, a metabolite of progesterone that interacts with GABA-A receptors, appears to behave differently in women with PMDD, contributing to anxiety and mood symptoms during the luteal phase.
Genetic factors play a role. Twin studies suggest 30 to 50 percent heritability. A 2017 study published in Molecular Psychiatry identified differences in ESC/E(Z) gene complex expression in cells from women with PMDD. Personal history of major depression, anxiety disorders, postpartum depression, and trauma raise risk. Per the Cleveland Clinic, PMDD is biologically distinct from depression that worsens premenstrually, though the two can overlap.
Symptoms
The DSM-5 criteria for PMDD require at least 5 symptoms during the luteal phase, with at least one being a core affective symptom. Affective symptoms include marked depression, hopelessness, or self-deprecating thoughts; marked anxiety or tension; marked affective lability; and persistent irritability, anger, or interpersonal conflict.
Other symptoms include decreased interest in usual activities, difficulty concentrating, fatigue, appetite changes or food cravings, sleep disturbance, feeling overwhelmed or out of control, and physical symptoms (breast tenderness, joint or muscle pain, bloating, weight gain). Symptoms must remit within a few days after menses onset and be absent in the week after menstruation. Suicidal ideation is more common in PMDD than in matched controls and warrants direct screening.
How PMDD Is Diagnosed
Diagnosis requires prospective symptom tracking across at least two consecutive cycles using validated tools such as the Daily Record of Severing of Problems (DRSP). Retrospective recall is unreliable because women with mood disorders often misattribute symptoms to the menstrual cycle. The DRSP is freely available and asks women to rate symptoms daily through 1 to 2 cycles.
Evaluation should also screen for and exclude conditions that mimic or coexist with PMDD, including major depressive disorder, persistent depressive disorder, generalized anxiety disorder, bipolar disorder, premenstrual exacerbation of an underlying mood disorder, thyroid dysfunction, and perimenopause-related mood symptoms. Substance use, medication side effects, and chronic medical conditions should be considered. Hormone testing is not diagnostic for PMDD because hormone levels in affected women are typically normal.
Treatment Options
SSRIs are first-line and have the strongest evidence base. Unlike treatment of major depression, SSRIs work rapidly in PMDD — often within 1 to 2 days — likely because they alter neurosteroid metabolism in addition to serotonin signaling. They can be dosed continuously or only during the luteal phase (typically days 14 to 28 of the cycle), with similar efficacy in many studies. Fluoxetine, sertraline, and paroxetine are FDA-approved for PMDD.
Hormonal options include drospirenone-containing combined oral contraceptives (Yaz, Beyaz), which have FDA approval for PMDD and reduce symptoms by suppressing ovulation. Continuous or extended-cycle dosing — minimizing or eliminating the hormone-free interval — produces better symptom control than traditional 21/7 regimens for many women with PMDD. According to a 2020 BMJ review, drospirenone-containing combined contraception is a reasonable first-line hormonal option.
For severe, refractory PMDD, GnRH agonists with add-back hormone therapy can be effective by inducing reversible medical menopause. Bilateral oophorectomy with hysterectomy is occasionally considered for severely affected women who have completed childbearing and have not responded to other treatments — a decision requiring careful multidisciplinary discussion. Detailed surgical management is covered separately. Lifestyle measures with reasonable evidence include regular aerobic exercise, calcium supplementation (1,200 mg daily), reducing alcohol and caffeine, and cognitive behavioral therapy.
When to See a Doctor
Schedule a visit if premenstrual symptoms significantly affect your work, relationships, or daily functioning, or if you experience suicidal thoughts during any phase of the cycle. Bringing two cycles of symptom diary data to the appointment substantially shortens the path to accurate diagnosis. A clinician comfortable with PMDD evaluation — typically gynecology or psychiatry — can help match treatment to symptom severity and pattern.
Women with personal or family history of mood disorders, postpartum depression, or perimenopausal mood symptoms benefit from earlier discussion. PMDD often coexists with other mental health conditions, and addressing underlying mood and anxiety disorders alongside cyclic treatment improves outcomes.
When to seek emergency care: Call 911, go to the nearest emergency room, or call or text 988 (Suicide and Crisis Lifeline) if you experience suicidal thoughts with intent or plan, thoughts of harming others, or any safety concern. PMDD-related suicidal ideation is real and warrants urgent care, not waiting for the cycle to turn.
Frequently Asked Questions
How is PMDD different from PMS?
PMS involves milder physical and mood symptoms in the luteal phase and is very common. PMDD is a distinct disorder requiring at least 5 symptoms with at least one core affective symptom, marked functional impairment, and DSM-5 criteria — it affects 3 to 8 percent of women versus the much larger group with PMS.
Do SSRIs work right away for PMDD?
Yes — that’s a key difference from major depression treatment. SSRIs typically reduce PMDD symptoms within 1 to 2 days of starting them, which makes luteal-phase-only dosing feasible for women who prefer to limit medication exposure.
Can birth control make PMDD worse?
It depends on the formulation and the individual. Drospirenone-containing combined contraception is FDA-approved for PMDD and helps many women, especially with continuous dosing. Other hormonal contraceptives can sometimes worsen mood symptoms. Tracking response is important; switching formulations or dosing patterns may be needed.
Does PMDD go away after menopause?
Yes, because it depends on cyclic hormonal changes. PMDD symptoms typically resolve once menstruation stops permanently. The perimenopausal years can be especially difficult because hormonal swings are unpredictable; symptoms often improve once full menopause is reached.
The Bottom Line
PMDD is a real, treatable medical condition — not a personal failing or just a worse version of PMS. Two cycles of prospective symptom tracking distinguishes PMDD from other mood disorders and dramatically improves diagnostic accuracy. SSRIs and drospirenone-containing combined contraception are first-line and help most women significantly. For severe cases, additional medical and rarely surgical options exist. A clinician familiar with PMDD diagnosis and treatment can make a meaningful difference in quality of life.